Table 6.
Energy decomposition of predicted ΔEbinding.
anti-VEGF | Favorable contributions of residues in anti-VEGF binding domain |
---|---|
Ranibizumab | Thr 105 (−56), Tyr 101 (−115), His 31(−129) |
Fab-bevacizumab | Ser 105 (−44), His 101 (−82), Asn 31 (−22) |
VEGFR1d2_R2d3 | Arg 154 (−171), Lys 157 (−190), Lys 165(−157), Lys 166 (−129), Arg 128 (−123), Lys 72 (−112), Lys 43 (−118), Lys 89 (−93), Arg 96 (−167) |
Values in brackets correspond to energy contribution of the residues (KJ/mol).